Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction in which antibodies (most commonly against acetylcholine receptors, or in some cases MuSK) block or destroy the receptor sites that muscle fibres use to receive nerve signals. The defining clinical feature is fatigable weakness -- muscle strength is relatively preserved at rest but decreases progressively with sustained or repeated use. This pattern has specific implications for walking aid use that differ from fixed-weakness conditions.
The Fatigability Pattern in MG
The fatigability of MG means that walking difficulty may not be apparent at the start of a walk and increases over time or distance:
- A patient may walk the first 100 metres without difficulty, then experience progressive leg heaviness and instability as the walk continues
- Weakness is typically proximal (hip flexors, quadriceps, shoulder girdle) in myasthenic limb weakness -- making it harder to lift the legs and maintain posture over time
- Symptoms fluctuate -- better in the morning (after overnight rest of the neuromuscular junction), worse in the evening and after exertion
- Heat and infection exacerbate MG symptoms -- walking in hot weather may trigger more rapid fatiguing
Walking Cane Indication in MG
A cane is not indicated in early MG where limb weakness is absent or mild. The cane becomes clinically relevant when:
- Proximal lower limb weakness (hip flexors, quadriceps) causes unsteady gait or fall risk during sustained walking
- Fatigue during community walking creates unsafe instability as the walk progresses
- The patient has reached a distance or activity threshold beyond which they are unsafe without support
Unlike conditions with fixed weakness, in MG the cane may be needed more as the walk progresses and less at the start -- a pattern that can confuse others who observe the patient walking without difficulty initially.
MG Treatment and Walking Improvement
MG is highly treatable. Pyridostigmine (acetylcholinesterase inhibitor), immunosuppressants (prednisolone, azathioprine, mycophenolate), and newer complement inhibitors (eculizumab, ravulizumab) can substantially reduce weakness. After treatment initiation or adjustment, walking capacity may improve significantly and cane need may reduce.
The implication: cane use in MG should be reassessed after treatment changes -- walking capacity is not static and cane requirement may change with treatment response.
MG Gait Features and Cane Use
| Feature | Implication for Walking | Cane Role |
|---|---|---|
| Fatigable proximal weakness | Worsening stability over distance | Provide stability in later phase of walk |
| Morning better / evening worse | Variable daily cane need | May not need cane in morning; use in evening or longer walks |
| Heat exacerbation | Summer walks trigger earlier fatigue | Cane use especially important in warm weather |
| Treatment response | Weakness may improve substantially | Reassess cane need after treatment changes |
| Myasthenic crisis risk | Respiratory and bulbar -- not gait-primary | Cane does not address crisis; crisis requires emergency care |
Explore the DaiWalk cane collection. Related: Walking Cane for Chronic Fatigue | Walking Cane Weaning: When and How to Reduce Cane Use
